RxDoctor Payments Data

Douglas Hamilton, MD

Dermatopathology · Woodland Hills, CANPI 1497815880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $941 and has fallen 97.4% since, to $25 in 2025.

$2,294in general payments, 2019–2025

Across 113 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$426
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$295
  • Sun Pharmaceutical Industries Inc.$261
  • Amgen$187
  • Mayne Pharma Commercial LLC$170
  • Pfizer$115
  • plus $840 from 17 others
$1,733in research payments, 2019–2025

Across 2 payments — averaging $866.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$2K

What the payments were for

  • Travel & lodging$90%
  • Food & beverage$2,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,294 in reported general payments places this provider in the 75th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California

Medicare billing

Part B allowed, 2024
$69,189
Medicare patients
135
Services billed
901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab11$73,705
Metronidazole14$1,218
Ketoconazole38$869
Betamethasone Dipropionate25$815
Clobetasol Propionate18$772
Triamcinolone Acetonide51$632
Mupirocin25$133
CefuroximeCefuroxime Axetil21$73
Hydroxyzine Hcl11$54

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Woodland Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →